Is Testosterone the “Fountain of Youth” for Aging Men?-Reference-Cited by-同舟云学术

Is Testosterone the “Fountain of Youth” for Aging Men?

Published:2023-02 Issue:2 Volume:23 Page:169-178
ISSN:1871-5303
Container-title:Endocrine, Metabolic & Immune Disorders - Drug Targets
language:en
Short-container-title:EMIDDT

Author:

Giagulli Vito Angelo¹²^ORCID,Lisco Giuseppe¹^ORCID,Mariano Francesco¹,De Tullio Anna¹,Triggiani Vincenzo¹^ORCID

Affiliation:

1. Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy

2. Outpatients Clinic of Endocrinology and Metabolic Disease, Conversano Hospital, Bari, Italy

Abstract

Background: Late-Onset Hypogonadism (LOH) is defined as a clinical and biochemical syndrome associated with advancing age. It is characterized by specific symptoms and less specific manifestations due to deficiency of serum testosterone (T) levels. Objective: This review aims to summarize the evidence related to LOH definition, diagnostic approach, and treatment to answer a clinical question: “Is Testosterone the fountain of youth for aging men?". Methodology: MEDLINE/PubMed and institutional websites were searched for original papers, guidelines, and position statements published in the last ten years. Results: Observational and randomized controlled studies on T replacement therapy in older men have been reported. Discussion and Conclusion: Despite some heterogeneities regarding diagnostic definition, therapeutic target, and testosterone prescription, all guidelines agreed that male hypogonadism should be diagnosed and managed in aged men as in adulthood. However, trials assessing the efficacy of T therapy conducted for male rejuvenating are lacking; thus, T prescription for this purpose is not recommended.

Publisher

Bentham Science Publishers Ltd.

Subject

Immunology and Allergy,Endocrinology, Diabetes and Metabolism

Reference97 articles.

1. Kaufman J.M.; Vermeulen A.; The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005,26(6),833-876

2. Kaufman J.M.; Lapauw B.; Mahmoud A.; T’Sjoen, G.; Huhtaniemi, I.T. Lapauw. B.; Mahmoud, A.; T’Sjoen, G.; Huhtaniemi, I.T. Aging and the male reproductive system. Endocr Rev 2019,40(4),906-972

3. Wu F.C.W.; Tajar A.; Beynon J.M.; Pye S.R.; Silman A.J.; Finn J.D.; O’Neill T.W.; Bartfai G.; Casanueva F.F.; Forti G.; Giwercman A.; Han T.S.; Kula K.; Lean M.E.; Pendleton N.; Punab M.; Boonen S.; Vanderschueren D.; Labrie F.; Huhtaniemi I.T.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010,363(2),123-135

4. Araujo A.B.; Esche G.R.; Kupelian V.; O’Donnell A.B.; Travison T.G.; Williams R.E.; Clark R.V.; McKinlay J.B.; Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007,92(11),4241-4247

5. Snyder P.J.; Bhasin S.; Cunningham G.R.; Matsumoto A.M.; Stephens-Shields A.J.; Cauley J.A.; Gill T.M.; Barrett-Connor E.; Swerdloff R.S.; Wang C.; Ensrud K.E.; Lewis C.E.; Farrar J.T.; Cella D.; Rosen R.C.; Pahor M.; Crandall J.P.; Molitch M.E.; Resnick S.M.; Budoff M.; Mohler E.R.; Wenger N.K.; Cohen H.J.; Schrier S.; Keaveny T.M.; Kopperdahl D.; Lee D.; Cifelli D.; Ellenberg S.S.; Lesson from the testosterone trials. Endocr Rev 2018,39(3),369-386